Tags

Type your tag names separated by a space and hit enter

An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Schizophr Res. 2005 Sep 15; 77(2-3):129-39.SR

Abstract

INTRODUCTION

Treatment-emergent tardive dyskinesia (TD) can be a serious side effect of antipsychotic treatment. Atypical antipsychotics are associated with a lower risk for TD than are conventional agents. A long-acting atypical antipsychotic, with more stable blood levels and lower peak blood levels than an oral formulation, may provide differential benefit regarding side effects, including movement disorders. This analysis assessed TD by defined research criteria in patients receiving long-acting, injectable risperidone.

METHODS

Clinically stable subjects with schizophrenia or schizoaffective disorder participated in a 50-week, open-label trial of long-acting, injectable risperidone. TD was studied by defined research criteria (Schooler, N.R., Kane, J.M., 1982. Research diagnosis for tardive dyskinesia. Arch. Gen. Psychiatry. 39, 486-487; Americal Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders, fourth ed. American Psychiatric Association, Washington, DC). The severity of dyskinesia and other movement disorders were rated by the Extrapyramidal Symptom Rating Scale (ESRS).

RESULTS

ESRS dyskinesia data were available for 662 patients. Five of 530 subjects without dyskinesia at baseline (0.94%) met the predefined criteria for emergent persistent TD during therapy. Based on either exposure to study medication or Kaplan-Meier analysis, the 1-year rate was 1.19%. Among the 132 subjects with dyskinesia at baseline, the mean score on the ESRS physician's exam for dyskinesia improved significantly at endpoint (-2.77; P<0.0001), regardless of anticholinergic drug use. (P=0.243 for patients with versus without anticholinergic drug use.)

CONCLUSIONS

In this open-label study, treatment with long-acting risperidone was associated with a low rate of emergent persistent TD. Significant improvement in existing dyskinesias was noted. The TD rate reported here is consistent with other reports of atypical antipsychotics and substantially lower than with conventional antipsychotics.

Authors+Show Affiliations

Medical Affairs Division, Janssen Pharmaceutica Products, L.P., 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200, USA. GGharaba@JANUS.JNJ.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15913962

Citation

Gharabawi, Georges M., et al. "An Assessment of Emergent Tardive Dyskinesia and Existing Dyskinesia in Patients Receiving Long-acting, Injectable Risperidone: Results From a Long-term Study." Schizophrenia Research, vol. 77, no. 2-3, 2005, pp. 129-39.
Gharabawi GM, Bossie CA, Zhu Y, et al. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res. 2005;77(2-3):129-39.
Gharabawi, G. M., Bossie, C. A., Zhu, Y., Mao, L., & Lasser, R. A. (2005). An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophrenia Research, 77(2-3), 129-39.
Gharabawi GM, et al. An Assessment of Emergent Tardive Dyskinesia and Existing Dyskinesia in Patients Receiving Long-acting, Injectable Risperidone: Results From a Long-term Study. Schizophr Res. 2005 Sep 15;77(2-3):129-39. PubMed PMID: 15913962.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. AU - Gharabawi,Georges M, AU - Bossie,Cynthia A, AU - Zhu,Young, AU - Mao,Lian, AU - Lasser,Robert A, PY - 2004/11/18/received PY - 2005/03/15/revised PY - 2005/03/17/accepted PY - 2005/5/26/pubmed PY - 2005/10/14/medline PY - 2005/5/26/entrez SP - 129 EP - 39 JF - Schizophrenia research JO - Schizophr Res VL - 77 IS - 2-3 N2 - INTRODUCTION: Treatment-emergent tardive dyskinesia (TD) can be a serious side effect of antipsychotic treatment. Atypical antipsychotics are associated with a lower risk for TD than are conventional agents. A long-acting atypical antipsychotic, with more stable blood levels and lower peak blood levels than an oral formulation, may provide differential benefit regarding side effects, including movement disorders. This analysis assessed TD by defined research criteria in patients receiving long-acting, injectable risperidone. METHODS: Clinically stable subjects with schizophrenia or schizoaffective disorder participated in a 50-week, open-label trial of long-acting, injectable risperidone. TD was studied by defined research criteria (Schooler, N.R., Kane, J.M., 1982. Research diagnosis for tardive dyskinesia. Arch. Gen. Psychiatry. 39, 486-487; Americal Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders, fourth ed. American Psychiatric Association, Washington, DC). The severity of dyskinesia and other movement disorders were rated by the Extrapyramidal Symptom Rating Scale (ESRS). RESULTS: ESRS dyskinesia data were available for 662 patients. Five of 530 subjects without dyskinesia at baseline (0.94%) met the predefined criteria for emergent persistent TD during therapy. Based on either exposure to study medication or Kaplan-Meier analysis, the 1-year rate was 1.19%. Among the 132 subjects with dyskinesia at baseline, the mean score on the ESRS physician's exam for dyskinesia improved significantly at endpoint (-2.77; P<0.0001), regardless of anticholinergic drug use. (P=0.243 for patients with versus without anticholinergic drug use.) CONCLUSIONS: In this open-label study, treatment with long-acting risperidone was associated with a low rate of emergent persistent TD. Significant improvement in existing dyskinesias was noted. The TD rate reported here is consistent with other reports of atypical antipsychotics and substantially lower than with conventional antipsychotics. SN - 0920-9964 UR - https://www.unboundmedicine.com/medline/citation/15913962/An_assessment_of_emergent_tardive_dyskinesia_and_existing_dyskinesia_in_patients_receiving_long_acting_injectable_risperidone:_results_from_a_long_term_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920-9964(05)00125-8 DB - PRIME DP - Unbound Medicine ER -